Truist Financial Issues Pessimistic Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD - Free Report) had its price objective reduced by Truist Financial from $16.00 to $15.00 in a research note released on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

Several other equities research analysts have also issued reports on the company. StockNews.com lowered Pediatrix Medical Group from a "buy" rating to a "hold" rating in a research report on Thursday, December 19th. Mizuho increased their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Tuesday, November 19th. Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They issued an "outperform" rating and a $18.00 price target for the company. Jefferies Financial Group increased their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, UBS Group lifted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Pediatrix Medical Group presently has an average rating of "Hold" and an average target price of $16.25.

Pediatrix Medical Group Stock Down 2.5 %

MD stock traded down $0.33 during mid-day trading on Monday, hitting $12.81. 467,111 shares of the company were exchanged, compared to its average volume of 457,604. The firm has a fifty day simple moving average of $14.35 and a 200 day simple moving average of $11.49. The company has a market capitalization of $1.10 billion, a PE ratio of -4.19, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period last year, the firm earned $0.29 earnings per share. The company's revenue for the quarter was up .9% compared to the same quarter last year. On average, research analysts forecast that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares of the company's stock, valued at approximately $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company's stock.

Institutional Trading of Pediatrix Medical Group

Institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP raised its holdings in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock worth $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. raised its stake in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock worth $7,725,000 after buying an additional 455,785 shares in the last quarter. Weiss Asset Management LP lifted its holdings in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after buying an additional 306,143 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock valued at $2,192,000 after buying an additional 251,072 shares in the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group during the second quarter worth about $1,721,000. 97.71% of the stock is owned by institutional investors and hedge funds.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.